PDF(Sci-hub)
Abstract：
UNASSIGNED: Thrombophilia is a condition that predisposes to a higher incidence of venous thromboembolisms (VTE), some also in atypical sites. Direct oral anticoagulants (DOACs) have proven to be effective in the treatment of deep vein thrombosis (DVT). However, their use can be sometimes challenging in particular settings of patients such as those with major thrombophilia - antithrombin, protein C and protein S deficiency, homozygous mutation of Factor V Leiden, homozygous mutation of Factor II G20210A, combined heterozygous mutation of factor V Leiden and Factor II G20210A - carrying a high thrombotic risk.
UNASSIGNED: At our Center, 45 patients with major thrombophilia were treated with DOACs: 33 after an initial treatment with vitamin K antagonists (VKA) and 12 as first-line therapy for VTE. The median follow-up of DOACs treatment was 29 months.
UNASSIGNED: No patient presented hemorrhagic or thrombotic complications during DOAC therapy. DOACs have proven to be effective and safe in this real-life series of patients with major thrombophilia.
UNASSIGNED: At our Center, 45 patients with major thrombophilia were treated with DOACs: 33 after an initial treatment with vitamin K antagonists (VKA) and 12 as first-line therapy for VTE. The median follow-up of DOACs treatment was 29 months.
UNASSIGNED: No patient presented hemorrhagic or thrombotic complications during DOAC therapy. DOACs have proven to be effective and safe in this real-life series of patients with major thrombophilia.
摘要：
■血栓性是一种易于发生静脉血栓栓塞（VTE）的疾病，有些也在非典型地点。直接口服抗凝剂（DOAC）已被证明可有效治疗深静脉血栓形成（DVT）。然而,它们的使用有时在患者的特定环境中具有挑战性，例如那些患有严重血栓形成的患者-抗凝血酶，蛋白C和蛋白S缺乏，因子VLeiden的纯合突变,因子IIG20210A的纯合突变,因子VLeiden和因子IIG20210A的组合杂合突变-携带高血栓风险。
■在我们的中心，45例患有严重血栓形成倾向的患者接受DOAC治疗：维生素K拮抗剂（VKA）初始治疗后33例，VTE一线治疗12例。DOACs治疗的中位随访时间为29个月。
■在DOAC治疗期间没有患者出现出血性或血栓性并发症。DOAC已被证明是有效和安全的，在这个现实生活中的一系列患者患有严重的血栓形成倾向。
■在我们的中心，45例患有严重血栓形成倾向的患者接受DOAC治疗：维生素K拮抗剂（VKA）初始治疗后33例，VTE一线治疗12例。DOACs治疗的中位随访时间为29个月。
■在DOAC治疗期间没有患者出现出血性或血栓性并发症。DOAC已被证明是有效和安全的，在这个现实生活中的一系列患者患有严重的血栓形成倾向。
